In July, the six viral marker assay conversion at CTS Dallas, Phoenix and Tampa laboratories was achieved with minimal disruption and substantial cost saving to our healthcare partners.
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).
In October, due to demand from existing healthcare partners, CTS began testing blood donors for anti...
As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...
In January, CTS is incorporated as a non-profit organization owned by Vitalant and OneBlood (formerl...
In April, CTS becomes the first blood donor testing organization in the US to implement Zika testing...
CTS Tampa lab implements Dengue testing on behalf of a healthcare partner in an endemic area.